Firefly Neuroscience Inc. Reveals Innovative Findings on the Efficacy of BNA™ as a Novel Approach to Managing Psychiatric Disorders

Saturday, September 16, 2023

Firefly Neuroscience Inc. is pleased to announce the groundbreaking results of an extensive study that investigated the potential benefits of utilizing Brain Network Analytics (BNA™) technology as a disease management program within the realm of psychiatric practice. This comprehensive research involved a cohort of 2,253 patients seeking treatment at a prominent psychiatric and multispecialty clinic in the United States.

At the core of Firefly Neuroscience's innovations lies the Brain Network Analytics (BNA™) platform, powered by artificial intelligence. Its practical implementation in a real-world clinical context has yielded promising results in enhancing the outcomes of psychiatric treatment. This study, with a specific focus on individuals diagnosed with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Attention-Deficit/Hyperactivity Disorder (ADHD), has unveiled valuable insights into how BNA™ technology could revolutionize disease management in the field of psychiatry.

Key highlights from the research include:

  • Enhanced Treatment Compliance: Patients grappling with depression, who underwent therapy guided by BNA™, exhibited a significant 15% increase in their adherence to MDD treatment protocols, encompassing both antidepressant medications and Transcranial Magnetic Stimulation (TMS).
  • Decreased Medication Alteration Necessity: The study demonstrated a noteworthy reduction of over 50% in the requirement to switch antidepressant medications among the patient population. This emphasizes the potential of BNA™ technology in optimizing medication selection and dosing.
  • Amplified Improvements in General Functionality: Individuals diagnosed with MDD, GAD, and ADHD experienced more than double the improvement in their overall general functioning when receiving BNA™-guided interventions. This suggests that BNA™ technology has the potential to comprehensively enhance patients' quality of life and daily functioning.
  • Elevated Rates of Antidepressant Response: The application of BNA™ technology was associated with a notable 10% increase in antidepressant response rates, signaling its potential to augment the effectiveness of traditional treatment approaches.
  • Reduction in Non-Responder Rates: Among MDD patients, the study observed a significant 17% decrease in the rate of treatment non-responders, indicating that BNA™ technology holds promise in mitigating treatment resistance and improving positive outcomes.

Firefly Neuroscience Inc. remains unwavering in its commitment to advancing the field of psychiatric and neurological care through its cutting-edge BNA™ technology. Their overarching mission is to enhance patient outcomes and contribute to the betterment of global mental health and cognitive disorder management.



Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitHealthcare CEO & Executive Strategy Summit